# Atelerix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atelerix

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.atelerix.co.uk
- Total disclosed funding: $0.6M
- Latest round: Seed (Jan 26, 2018)
- Investors on record: 4

## About

Atelerix Ltd. is a biotechnology company based in Cambridge, UK, specializing in innovative cell preservation technology that enhances the transportation of live cells, tissues, and viruses at room temperature.Founded in 2017 in Cambridge, UK, Atelerix Ltd. focuses on developing solutions for cell preservation, avoiding the complexities of cryopreservation. The company has completed a total of 6 deals, with their most recent funding round occurring on July 22, 2024, where they raised GBP 750,000 from investors including ACF Investors and o2h Ventures. The founders, Che Connon and Stephen Swioklo, have worked on establishing a strong technological foundation to support the needs of their clients. The current CEO is Alastair Carrington, with Mick McLean contributing to the leadership team.Atelerix specializes in innovative cell preservation technology, leveraging hypothermic gel-based solutions to maintain the viability of live cells, tissues, and viruses during transport. Their core offerings support the shipping of various biological materials including suspended and adherent cells, leukapheresis material, primary tissues, organoids, spheroids, and multi-well plates. This technology eliminates the need for cryopreservation, allowing samples to be safely shipped at room temperature, simplifying logistics and reducing costs for laboratories and research institutions. Atelerix caters to a diverse client base, including pharmaceutical companies, biotech firms, and academic institutions across Europe, North America, and Asia, which rely on their products for drug development, clinical research, and therapeutic applications.Atelerix generates revenue through direct sales of its cell preservation products primarily targeting the biotechnology and pharmaceutical sectors. Their business model emphasizes B2B transactions, with clients purchasing products as needed or establishing long-term agreements for regular supply. The pricing structure remains competitive, reflecting the advanced technology and sustainability benefits of their offerings, including specialized preservation kits tailored to specific biological materials. By providing flexible shipping solutions, Atelerix positions itself as a vital partner in the biological and medical research landscape.Following their most recent funding round in July 2024, where Atelerix Ltd raised GBP 750,000, the company plans to enhance its branding and sales efforts to drive technology adoption. Future initiatives include the development of new products aimed at expanding their product range and entering additional markets. Atelerix intends to target growth in specific geographic regions and aims to solidify its presence in North America and Asia by the end of 2025. The funds will be utilized to bolster marketing strategies and sales operations to support these ambitious expansion plans.

## Funding rounds

- Seed, Jan 26, 2018, $0.6M — Oxford Technology Management, Future Planet Capital Regional, Angels in MedCity, Newable

## Investors

- Oxford Technology Management (https://capitalatlas.ai/funds/oxford-technology-management) — Seed
- Future Planet Capital Regional (https://capitalatlas.ai/funds/future-planet-capital-regional) — Seed
- Angels in MedCity — Seed
- Newable (https://capitalatlas.ai/funds/newable) — Seed